secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000875320-22-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B
--------------------------------------------------------------------------------

- Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.
- GAAP diluted EPS $3.13; non-GAAP diluted EPS $3.60.
- Raised full-year 2022 product revenue guidance to $8.6-$8.8B from prior $8.4-$8.6B.
- Clinical updates: exa-cel (sickle cell/beta thalassemia) and VX-880 (type 1 diabetes) data demonstrate transformative potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/0000875320-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/vrtx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer